ENVARSUS XR (tacrolimus)
Envarsus XR helps prevent organ rejection in patients who have recently undergone a kidney transplant. It is also used for stable kidney transplant patients who are switching from immediate-release versions of tacrolimus to this formulation. In both cases, the medication is used in combination with other immunosuppressive drugs to help the body's immune system accept the new kidney.
How ENVARSUS XR Works
This medication works by binding to an intracellular protein to block the activity of calcineurin, an enzyme involved in the immune response. This process prevents the production of several cytokines and inhibits the activation and growth of T-lymphocytes. By suppressing these specific immune cells, the drug helps prevent the body from attacking and rejecting a transplanted kidney.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2015-07-10
- Patent Cliff
- 2028
- Routes
- ORAL
- Dosage Forms
- TABLET, EXTENDED RELEASE
ENVARSUS XR Approval History
What ENVARSUS XR Treats
1 indicationsENVARSUS XR is approved for 1 conditions since its original approval in 2015. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Organ Rejection
ENVARSUS XR Boxed Warning
MALIGNANCIES AND SERIOUS INFECTIONS Increased risk for developing serious infections and malignancies with ENVARSUS XR or other immunosuppressants that may lead to hospitalization or death [see Warnings and Precautions (5.1 , 5.2 )]. WARNING: MALIGNANCIES AND SERIOUS INFECTIONS See full prescribing information for complete boxed warning. Increased risk for developing serious infections and malignancies with ENVARSUS XR or other immunosuppressants that may lead to hospitalization or death. ( 5.1 ...
WARNING: MALIGNANCIES AND SERIOUS INFECTIONS Increased risk for developing serious infections and malignancies with ENVARSUS XR or other immunosuppressants that may lead to hospitalization or death [see Warnings and Precautions (5.1 , 5.2 )]. WARNING: MALIGNANCIES AND SERIOUS INFECTIONS See full prescribing information for complete boxed warning. Increased risk for developing serious infections and malignancies with ENVARSUS XR or other immunosuppressants that may lead to hospitalization or death. ( 5.1 , 5.2 )
ENVARSUS XR Target & Pathway
ProTarget
ENVARSUS XR Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Direct competitors
Same target(s) AND same indication — head-to-head.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to ENVARSUS XR
3 of 16FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
379 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT07524530 | 10002233 002233-C | Ph 2 | not yet recruiting | Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers |
| NCT05088356 | IRB-60439 NCI-2021-12228 | Ph 1 | active not recruiting | Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft |
| NCT07582172 | 25663 NCI-2026-03208, 25663 | Ph 2 | not yet recruiting | Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome |
| NCT07204275 OLYMPUS | VX24-AIS-D10 2025-521661-27-00 | Ph 2, Ph 3 | recruiting | Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) |
| NCT06996119 | 23822 NCI-2025-03603, 23822 | Ph 1 | recruiting | Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant |
| NCT05027945 | 10000404 000404-C | Ph 2 | recruiting | A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome |
| NCT01861106 | 130132 13-C-0132 | Ph 2 | recruiting | Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations |
| NCT07566377 | 26-168 | Ph 2 | recruiting | Cord Blood Transplantation in Children and Young Adults With Blood Cancer |
| NCT06962800 PROMINENT | 299PN301 2024-519232-16-00 | Ph 3 | recruiting | A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN) |
| NCT03670966 | RG1003349 10060, P30CA015704 | Ph 1, Ph 2 | recruiting | 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome |
| NCT03816332 results posted | NCI-2019-00239 NCI-2019-00239, ETCTN10214 | Ph 1 | active not recruiting | Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers |
| NCT06195891 | 23343 NCI-2023-08816, 23343 | Ph 1 | recruiting | Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome |
| NCT06807606 | 2024-1605 NCI-2025-00794 | Ph 2 | recruiting | Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation |
| NCT07412470 FREXERA | EFC18554 2025-521521-33-00 | Ph 2, Ph 3 | recruiting | A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation |
| NCT07548983 | STUDY00028015 NCI-2025-09157, STUDY00028015 | Ph 1 | not yet recruiting | Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation |
| NCT07302776 | IRB-82367 | Ph 1 | not yet recruiting | TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT |
| NCT07493538 | 2025LS162 | Ph 2 | recruiting | MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases |
| NCT07349771 | MC230810 24-009803 | Ph 2 | not yet recruiting | Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial |
| NCT06828796 | NSH 1420 | Ph 2 | recruiting | Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide |
| NCT04859946 | 2020-0971 NCI-2021-02784, 2020-0971 | Ph 2 | active not recruiting | Itacitinib for the Prevention of Graft Versus Host Disease |
| NCT04177004 | 19214 NCI-2019-06454, 19214 | Ph 1 | suspended | Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant |
| NCT03856216 results posted | 2018-0860 NCI-2019-00531, 2018-0860 | Ph 2 | terminated | Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation |
| NCT01384513 results posted | 11D.247 2011-31, JT 1795 | Ph 2 | completed | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies |
| NCT04384692 | RG1006507 NCI-2020-01626, 10093 | Ph 2 | active not recruiting | Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis |
| NCT03640026 GLITTER | CHD045-17 | Ph 4 | terminated | Glucose Disorders Induced by Tacrolimus on Pre Transplantation Endstage Renal Disease Patients |
| NCT03769298 | 2018-0821 A539742, SMPH/SURGERY/TRANSPLANT | Ph 2, Ph 3 | recruiting | CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients |
| NCT00792948 results posted | NCI-2009-00800 NCI-2009-00800, S0805 | Ph 2 | active not recruiting | Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia |
| NCT06084780 TRANSCAPE | CASE7Z23 | Ph 2 | not yet recruiting | Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE) |
| NCT05736419 | 23-009 | Ph 2 | recruiting | A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) |
| NCT06478017 | DAIT RTB-013 | Ph 2 | recruiting | Belatacept in Heart Transplantation |
| NCT04629248 MAJESTY | WA41937 2020-003233-38, 2023-506525-11-00 | Ph 3 | active not recruiting | A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy |
| NCT02891603 results posted | MCC-18783 5R01HL133823-02 | Ph 1, Ph 2 | completed | A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression |
| NCT03605927 | MCC-19305 | Ph 1 | completed | CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease |
| NCT02918292 CHAMP results posted | BMT CTN 1502 2U10HL069294-11, 5U24CA076518 | Ph 2 | completed | Optimizing Haploidentical Aplastic Anemia Transplantation (BMT CTN 1502) |
| NCT02333162 | IRB14-0709 NCI-2014-02469, IRB14-0709 | Ph 1 | suspended | Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant |
| NCT04339101 results posted | 19576 NCI-2020-01722, 19576 | Ph 2 | completed | Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation |
| NCT02251821 results posted | 9033 NCI-2014-01882, 9033 | Ph 2 | completed | JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis |
| NCT01659606 | 12-950 IRB-P00003466 | Ph 2 | active not recruiting | Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita |
| NCT03321656 | 42753 | Ph 2, Ph 3 | recruiting | Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile |
| NCT03663335 CIRRUS I results posted | CCFZ533A2201 2017-003607-22 | Ph 2 | completed | Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients |
| NCT07214688 | Pro2025-0254 FLU-TBI-800-PTCY | Ph 2 | recruiting | Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies |
| NCT04904588 ACCESS | ACCESS | Ph 2 | active not recruiting | HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide |
| NCT03663933 results posted | 180135 18-C-0135 | Ph 2 | active not recruiting | Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation |
| NCT01804634 | J12106 NA_00076243, 5P01CA225618-06 | Ph 2 | recruiting | Reduced Intensity Haploidentical BMT for High Risk Solid Tumors |
| NCT03970096 | RG1005364 9749, NCI-2019-03188 | Ph 2 | recruiting | Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) |
| NCT05622318 | PRO00046962 | Ph 2 | active not recruiting | De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis |
| NCT06872333 | 2024LS140 | Ph 2 | recruiting | Allo HSCT for High Risk Hemoglobinopathies |
| NCT06345495 | 2023-0899 NCI-2024-02814 | Ph 2 | recruiting | High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly |
| NCT04965597 | BMTCTN1904 2U10HL069294-11, RG1121820 | Ph 2 | completed | Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904) |
| NCT06638879 | 2023-0687 | Ph 1 | completed | Tacrolimus Toothpaste for Management of Oral Chronic Graft vs. Host Disease (cGVHD) |
Showing 50 of 379 trials
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ENVARSUS XR FDA Label Details
Indications & Usage
FDA Label (PDF)ENVARSUS XR is indicated for the treatment of Organ Rejection.
WARNING: MALIGNANCIES AND SERIOUS INFECTIONS Increased risk for developing serious infections and malignancies with ENVARSUS XR or other immunosuppressants that may lead to hospitalization or death [see Warnings and Precautions (5.1 , 5.2 )]. WARNING: MALIGNANCIES AND SERIOUS INFECTIONS See full pre...
ENVARSUS XR Patents & Exclusivity
Patents (10 active)
Pro Intelligence Preview
Deep insights for ENVARSUS XR
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2028
- • 135 active patents
Trial Analysis
- • 395 total trials
- • Stage: Stable
Competitive Landscape
- • 16 similar drugs
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment